| Major clinical outcomes in antiretroviral therapy (ART)–naive participants and in those not receiving ART at baseline in the SMART study Strategies for Management of Antiretroviral Therapy (SMART) Study Group The Journal of infectious diseases 197 (8), 1133-1144, 2008 | 577 | 2008 |
| Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis‐4 score and aspartate … JA Bachofner, PV Valli, A Kröger, I Bergamin, P Künzler, A Baserga, ... Liver International 37 (3), 369-376, 2017 | 313 | 2017 |
| Inferior Clinical Outcome of the CD4+ Cell Count–Guided Antiretroviral Treatment Interruption Strategy in the SMART Study: Role of CD4+ Cell Counts and HIV … Strategies for Management of Antiretroviral Therapy (SMART) Study Group The Journal of infectious diseases 197 (8), 1145-1155, 2008 | 259 | 2008 |
| Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy JP Zuber, A Calmy, JM Evison, B Hasse, V Schiffer, T Wagels, R Nuesch, ... Clinical infectious diseases 38 (8), 1178-1185, 2004 | 252 | 2004 |
| Antithrombotic treatment with direct‐acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis A De Gottardi, J Trebicka, C Klinger, A Plessier, S Seijo, B Terziroli, ... Liver International 37 (5), 694-699, 2017 | 240 | 2017 |
| High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients NJ Mueller, CA Fux, B Ledergerber, L Elzi, P Schmid, T Dang, L Magenta, ... Aids 24 (8), 1127-1134, 2010 | 228 | 2010 |
| Patterns of resistance-associated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals J Dietz, S Susser, J Vermehren, KH Peiffer, G Grammatikos, A Berger, ... Gastroenterology 154 (4), 976-988. e4, 2018 | 174 | 2018 |
| Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial SMART Study Group* Annals of internal medicine 149 (5), 289-299, 2008 | 167 | 2008 |
| Homocysteinaemia in HIV-infected patients treated with highly active antiretroviral therapy E Bernasconi, M Uhr, L Magenta, A Ranno, A Telenti, ... Aids 15 (8), 1081-1082, 2001 | 61 | 2001 |
| Efficacy of low-dose intermittent subcutaneous interleukin (IL)–2 in antiviral drug–experienced human immunodeficiency virus–infected persons with detectable virus load: a … G Tambussi, S Ghezzi, S Nozza, G Vallanti, L Magenta, M Guffanti, ... The Journal of infectious diseases 183 (10), 1476-1484, 2001 | 61 | 2001 |
| Small dense lipoproteins, apolipoprotein B, and risk of coronary events in HIV-infected patients on antiretroviral therapy: the Swiss HIV Cohort Study HC Bucher, W Richter, TR Glass, L Magenta, Q Wang, M Cavassini, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 60 (2), 135-142, 2012 | 37 | 2012 |
| Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy J Dietz, VC Di Maio, A de Salazar, D Merino, J Vermehren, S Paolucci, ... Journal of Hepatology 74 (4), 801-810, 2021 | 27 | 2021 |
| Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland J Bachofner, PV Valli, I Bergamin, A Kröger, P Künzler, A Baserga, ... Swiss medical weekly 148, w14560, 2018 | 27 | 2018 |
| Metabolic changes in HIV-infected patients treated with protease inhibitors E Bernasconi, A Carota, L Magenta, M Pons, M Russotti, T Moccetti 12th World AIDS Conference, 1998 | 27 | 1998 |
| Efficacy of retreatment after failed direct-acting antiviral therapy in patients with HCV Genotype 1–3 infections J Dietz, U Spengler, B Müllhaupt, JS Zur Wiesch, F Piecha, S Mauss, ... Clinical Gastroenterology and Hepatology 19 (1), 195-198. e2, 2021 | 16 | 2021 |
| Swiss HIV Cohort Study Group et al. Pulmonary arterial hypertension related to HIV infection: Improved hemodynamics and survival associated with antirretroviral therapy JP Zuber, A Calmy, JM Evison, B Hasse, V Schiffer, T Wagels, R Nuesch, ... Clin Infect Dis 38 (8), 1178-1185, 2004 | 12 | 2004 |
| Addressing barriers to hepatitis C virus (HCV) elimination: real-world outcomes in historically underserved patients with chronic HCV infection treated with glecaprevir … P Lampertico, M Peck-Radosavljevic, MI Bondin, W Mazur, L Magenta, ... Hepatology 70, 954A-955A, 2019 | 10 | 2019 |
| the Swiss HIV Cohort Study High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients NJ Mueller, CA Fux, B Ledergerber, L Elzi, P Schmid, T Dang, L Magenta, ... Aids 24, 1127-34, 2010 | 10 | 2010 |
| Lipid and lipoprotein profile in HIV-infected patients treated with lopinavir/ritonavir as a component of the first combination antiretroviral therapy L Magenta, S Dell-Kuster, WO Richter, J Young, B Hasse, M Flepp, ... AIDS research and human retroviruses 27 (5), 525-533, 2011 | 9 | 2011 |
| Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure J Dietz, B Müllhaupt, P Buggisch, C Graf, KH Peiffer, K Matschenz, ... Journal of hepatology 78 (1), 57-66, 2023 | 8 | 2023 |
